Anticoagulants: Difference between revisions
No edit summary |
|||
| Line 26: | Line 26: | ||
**[[Dalteparin]] | **[[Dalteparin]] | ||
==Factor Xa Inhibitors== | ==Parenteral Factor Xa Inhibitors== | ||
*[[Fondaparinux]] | |||
==Direct oral anticoagulants (DOACs)== | |||
===Factor Xa Inhibitors=== | |||
''Inhibits Factor Xa, leading to inactivation of thrombin '' | ''Inhibits Factor Xa, leading to inactivation of thrombin '' | ||
*[[Rivaroxaban]] (Xarelto) | *[[Rivaroxaban]] (Xarelto) | ||
*[[Apixaban]] (Eliquis) | *[[Apixaban]] (Eliquis) | ||
*[[Edoxaban]] | *[[Edoxaban]] | ||
==Direct Thrombin Inhibitors== | ===Direct Thrombin Inhibitors=== | ||
''Directly inhibits thrombin'' | ''Directly inhibits thrombin'' | ||
*[[Dabigatran]] | *[[Dabigatran]] | ||
Latest revision as of 16:39, 18 October 2023
Contraindications to Anticoagulation[1]
- Absolute:
- Active bleeding
- Severe bleeding diathesis or platelet count <20K
- Neurosurgery, ocular surgery, or intracranial bleeding in the last 10 days
- Relative:
- Mild-to-moderate bleeding diathesis or thrombocytopenia
- Brain metastases
- Recent major trauma
- Major abdominal surgery within the past 2 days
- GI or GU bleeding within the past 14 days
- Endocarditis
- Severe hypertension (>200/120mmHg) at presentation
Vitamin K Antagonist
Blocks activation of vitamin K dependent prothrombotic factors II, VII, IX, X and blocks synthesis of vitamin K dependent ANTI-thrombotic proteins C and S
Heparins
Bind to and activate antithrombin, which in turns inactivates factor Xa and thrombin
Parenteral Factor Xa Inhibitors
Direct oral anticoagulants (DOACs)
Factor Xa Inhibitors
Inhibits Factor Xa, leading to inactivation of thrombin
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- Edoxaban
Direct Thrombin Inhibitors
Directly inhibits thrombin
See Also
- Anticoagulant reversal for life-threatening bleeds
- Antiplatelet medications
- Procedures in patients with coagulopathies
References
- ↑ Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.